Evaluation of Different Doses of Letrozole in Ectopic Pregnancy

Last updated: January 15, 2022
Sponsor: Zagazig University
Overall Status: Completed

Phase

4

Condition

Pregnancy

Treatment

N/A

Clinical Study ID

NCT05198141
LETROZOLE ON ECTOPIC PREGNANCY
  • Ages 19-35
  • Female

Study Summary

The utilization of letrozole at a daily dose of 10 mg for medical treatment of ectopic pregnancy considerably has a high success rate without imposing any serious side effects compared to daily 5mg letrozole.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosed ectopic pregnancy was by
  • Absence of an intrauterine gestational sac on vaginal ultrasound Coupled with
  • β-hCG titers beyond the discrimination zone of at least 2,000 milli-Internationalunits (mIU/m).

Exclusion

Exclusion Criteria:

  • Patients had contraindications for letrozole
  • Patients with any systemic disease ( diabetes, hypertension, ....)
  • Patients with b-hCG levels >3,000 mIU/mL
  • Patients with hemoglobin level <10 g/dL,
  • Patients with platelets count <150,000/mL,
  • Patients with elevated liver enzymes,
  • Patients with elevated blood urea, or serum creatinine
  • The presence of a fetal heartbeat in a gestational sac detected outside the uterinecavity

Study Design

Total Participants: 60
Study Start date:
December 15, 2020
Estimated Completion Date:
January 01, 2022

Study Description

Letrozole, an aromatase inhibitor, has recently been introduced as favorable medical treatment for ectopic pregnancy. We aimed at evaluating the effects of different doses of letrozole for induction of abortion Sixty patients with undisturbed ectopic pregnancy were classified into three equal groups. Group I: The control group that contained women who were undergoing laparoscopic salpingectomy, Group II: Patients who received letrozole (5 mg d-1) for 10 d, and Group III: Patients who received letrozole (10 mg d-1) for 10 d. After that, the human chorionic gonadotropin (β-hCG) levels were determined for the first day and after 11 d of treating. letrozole (10 mg d-1) markedly reduced the receptors of estrogen and progesterone, and subsequent vascular endothelial growth factor signals, resulting in marked apoptosis in the placenta tissue. The utilization of letrozole at a dose of 10 mg d-1 for inducement of abortion typically results in a substantial high-successful rate without any severe side effects.

Connect with a study center

  • Mohamed ALI Alabiad

    Zagazig, Sharkia 14150
    Egypt

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.